CSF1R-IN-22
CAS No. 2095849-04-8
CSF1R-IN-22( —— )
Catalog No. M13301 CAS No. 2095849-04-8
CSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 200 | Get Quote |
|
| 10MG | 309 | Get Quote |
|
| 25MG | 521 | Get Quote |
|
| 50MG | 746 | Get Quote |
|
| 100MG | 1035 | Get Quote |
|
| 500MG | 2052 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCSF1R-IN-22
-
NoteResearch use only, not for human use.
-
Brief DescriptionCSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM.
-
DescriptionCSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM, displays 120-fold selectivity over c-Kit; has improved metabolic stability and Caco2 permeability.
-
In VitroCSF1R is thought to play an important role in recruitment and differentiation of tumor-associated macrophages (TAMs). CSF1R-IN-1 (compound 22) shows good intestinal permeability in a Caco2 assay.
-
In VivoCSF1R-IN-1 has favorable pharmacokinetics when dosed orally to mice. It appears suitable for in vivo pharmacology testing in the appropriate preclinical tumor model to demonstrate proof of concept.. Animal Model:Male CD-1 mice, 25-35 grams (8-11 weeks old)Dosage:2 mg/kg IV or 10 mg/kg orally (Per Os)Administration:i.v. or oralResult:I.V.: Cmax=3.55, T1/2=0.87P.O.: Cmax=4.6, T1/2=1.8, Bioavailability=64%
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
RecptorCSF1R
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2095849-04-8
-
Formula Weight479.463
-
Molecular FormulaC25H20F3N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (173.80 mM)
-
SMILESCC1=CC=C(NC(C2=CC=CC(C(F)(F)F)=C2)=O)C=C1NC(C3=CC(C4=CN(C)N=C4)=CN=C3)=O
-
Chemical Name5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ramachandran SA, et al. Bioorg Med Chem Lett. 2017 May 15;27(10):2153-2160.
molnova catalog
related products
-
Edicotinib
Edicotinib (JNJ 40346527, PRV 6527) is a potent, selective, orally bioavailable CSF-1R inhibitor with IC50 of 3.2 nM; shows weak affinity for KIT and FLT3 (IC50= 20 nM and 190 nM, respectively).
-
GW2580
A potent, selective c-Fms (CSF1R) inhibitor that completely inhibits human cFMS kinase in vitro at 60 nM.
-
Vimseltinib
DCC-3014 is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM) extracted from the patent WO2014145025A2 (Example 10).
Cart
sales@molnova.com